Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 ...

The collaboration marks an “evolution” in the pharmaceutical giant’s use of AI and adds to a series of broad deals its peers ...

Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antitrust suit.

Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can ...

Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?

Once a drug lost primary patent protection or hit a certain age, it was managed for steady — if declining — cash flow with ...

The agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron and an obesity pill is headed toward an approval in China.

While early, the findings suggest the therapy could be superior to Novartis’ Vijoice at treating “vascular anomalies,” a ...

Tested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring ...

The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ...

Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” ...

A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a ...